EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

Alessandra Vergori iD, Alessandro Cozzi-Lepri, Sergio Lo Caputo, Alessandro Tavelli iD, Valentina Mazzotta iD, Elisabetta Schiaroli, Giancarlo Orofino, Cristina Mussini, Silvia Nozza iD, Antonella Cingolani, Andrea Antinori iD, Antonella d'Arminio Monforte und 1 weitere

Journal of Antimicrobial Chemotherapy · 04.11.2025 · 80 (11) · 3082-3091

DOI: 10.1093/jac/dkaf345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 23.09.2025. Verfasst von Alessandra Vergori und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: HIV Infections, Lamivudine, Anti-HIV Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare, Icona Foundation, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This analysis aimed to evaluate the rate of failure of first-line lamivudine/dolutegravir in a real-world setting and assess the effectiveness among people with HIV (PWH) at higher risk of suboptimal response.

Methods

The study included PWH from the ICONA cohort who started first-line lamivudine/dolutegravir between 2016 and 2024. The primary endpoint was time to treatment failure (TF), defined as virological failure (VF, two consecutive HIV-RNA of >50 copies/mL >6 months after treatment initiation) or discontinuation due to toxicity/lack virological control/non-adherence or death for any cause. Secondary endpoints were time to treatment discontinuation for any reason (TD) and pure VF. Main exposures of interest were baseline CD4 and HIV-RNA, age, sex at birth and nation of birth. Standard survival analysis and Cox regression models were used.

Results

Among 446 participants, after a median follow-up of 22 months, 4.3% (n = 19) experienced TF, the 3 year cumulative probability was 5.8% (95% CI: 2.9%–8.7%). Baseline CD4 count was associated with a 3-fold higher risk of TF, which decreased after adjustments. Higher viral loads (>100 000 copies/mL), age >50 years and foreign-born status were also associated with an increased risk of TF. No differences in TF according to sex at birth were found. By 3 years the probabilities of TD and VF were 13.4% (95% CI: 9.1%–17.6%) and 2.3% (95% CI: 0.19%–4.4%), respectively.

Conclusions

In our real-world setting, the TF probability for first-line lamivudine/dolutegravir was below 6% at 3 years, lower than in randomized trials. Our data suggest that, as shown with other regimens, PWH starting lamivudine/dolutegravir with CD4 count of ≤200 cells/mm3, HIV-RNA of >100 000 copies/mL, older age or foreign-born status may be at higher risk of TF, though larger studies are needed to qualify the magnitude of the effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLamivudineAnti-HIV AgentsHumansMaleFemaleAdultMiddle AgedViral LoadCD4 Lymphocyte CountTreatment FailureCohort StudiesTreatment OutcomeRNA, Viral

Substanzen

LamivudineAnti-HIV AgentsRNA, Viral

Autor:innen und Institutionen

  • Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
  • Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
  • Infection Diseases Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
  • Icona Foundation, Milan, Italy.
  • National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
  • Department of Infectious Diseases, University of Perugia, Perugia, Italy.

ORCID-Profile: Alessandra Vergori, Alessandro Tavelli, Valentina Mazzotta, Silvia Nozza, Andrea Antinori

Förderung

  • ViiV Healthcare
  • Icona Foundation
  • Gilead Sciences
  • Merck Sharpe & Dohme
  • Italian Ministry of Health
  • Linea 2-progetto 2

Zitieren

APA

Vergori, A., Cozzi-Lepri, A., Lo Caputo, S., Tavelli, A., Mazzotta, V., Schiaroli, E., Orofino, G., Mussini, C., Nozza, S., Cingolani, A., Antinori, A., d'Arminio Monforte, A., & Icona Foundation Study Group (2025). Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort. Journal of Antimicrobial Chemotherapy, 80(11), 3082-3091. https://doi.org/10.1093/jac/dkaf345

Vancouver

Vergori A, Cozzi-Lepri A, Lo Caputo S, Tavelli A, Mazzotta V, Schiaroli E, et al. Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort. Journal of Antimicrobial Chemotherapy. 2025;80(11):3082-3091. doi:10.1093/jac/dkaf345

BibTeX
@article{Vergori2025,
  author = {Vergori, Alessandra and Cozzi-Lepri, Alessandro and Lo Caputo, Sergio and Tavelli, Alessandro and Mazzotta, Valentina and Schiaroli, Elisabetta and Orofino, Giancarlo and Mussini, Cristina and Nozza, Silvia and Cingolani, Antonella and Antinori, Andrea and d'Arminio Monforte, Antonella and Icona Foundation Study Group, Icona Foundation Study Group},
  title = {Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {11},
  pages = {3082--3091},
  doi = {10.1093/jac/dkaf345}
}
Kostenlos starten →